Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
NervGen Pharma Corp. (NGEN) had Income from Continuous Operations of -31.57M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
-31.57M |
|
-- |
|
-- |
|
17.95M |
|
-17.95M |
|
-13.63M |
|
-31.57M |
|
-31.57M |
|
-31.57M |
|
|
Income from Continuous Operations |
-31.57M |
-31.57M |
|
-31.57M |
|
-17.95M |
|
-17.91M |
|
72.33M |
|
72.33M |
|
-0.44 |
|
-0.44 |
|
| Balance Sheet Financials | |
16.32M |
|
-- |
|
0.29M |
|
16.61M |
|
14.12M |
|
-- |
|
-- |
|
14.12M |
|
2.49M |
|
2.20M |
|
2.49M |
|
79.65M |
|
| Cash Flow Statement Financials | |
-13.96M |
|
0.07M |
|
17.01M |
|
12.36M |
|
15.80M |
|
3.44M |
|
3.86M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.16 |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-13.96M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-1268.86% |
|
-1438.09% |
|
-190.08% |
|
-1268.86% |
|
0.03 |
|
-0.19 |
|
-0.19 |
|